Skip to main content

Table 2 The changes in DM patients' inflammation parameters.

From: Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment

Parameters HC Metformin (months) Rosiglitazone (months)
   0 1 2 0 2
WBC × 10 9 6.7 ± 0.1 7.3 ± 0.3b 7.4 ± 0.4 7.5 ± 0.2 7.04 ± 0.5b 6.8 ± 0.6
PMNLs × 10 9 4.0 ± 0.1 4.6 ± 0.3b 4.7 ± 0.2 4.9 ± 0.1 4.2 ± 0.4b 4.4 ± 0.5
PMNL apoptosis (%) 4.0 ± 0.1 12.7 ± 3.4b 9.5 ± 2.8a, b 6.5 ± 1.0a 20.4 ± 4.4b 7.5 ± 1.9a
Monocytes × 10 9 0.36 ± 0.02 0.44 ± 0.05b 0.40 ± 0.04b 0.39 ± 0.04a 0.49 ± 0.03b 0.39 ± 0.01a
Fibrinogen (mg/dl) 304.6 ± 17.6 440.1 ± 25.2b 471.1 ± 28.8b 415.9 ± 41.2a, b 400 ± 16.6b 332.8 ± 8.1a,b
Albumin (g/dl) 4.6 ± 0.05 4.53 ± 0.1 4.74 ± 0.1 4.7 ± 0.04 4.5 ± 0.1 4.6 ± 0.1
Transferrin (g/dl) 273.2 ± 10.6 274.6 ± 8.4 276.7 ± 7.2 287.9 ± 7.7 264.7 ± 7.6 286.2 ± 8.9
CRP (mg/L) 1.5 ± 0.1 8.3 ± 1.6b 6.6 ± 1.1b 5.8 ± 1.5a, b 4.3 ± 0.9b 1.8 ± 0.2a,b
  1. a P < 0.05, treated DM patients vs. untreated DM patients;
  2. b P < 0.05, untreated DM patients vs. HC subjects